Curevac NV and The University of Texas MD Anderson Cancer Center have entered into a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
Recent genome-wide association studies identified an association between low bone mineral density (BMD) and a single-nucleotide polymorphism (SNP) at the MALAT1 locus, but there is no functional evidence on the role of MALAT1 alterations in BMD or osteoporosis. Hence, scientists at MD Anderson Cancer Center aimed to assess the functional role of MALAT1 alterations in low BMD and osteoporosis.
Researchers from Sun Yat-Sen University and MD Anderson Cancer Center have compared the proteins secreted by hepatocellular carcinoma (HCC) cells in responders and nonresponders to the anti-PD-1 antibody nivolumab.
It has been previously demonstrated that genetic variability of thioredoxin reductase 1 (TXNRD1) is associated with aging and age-associated phenotypes. Researchers from MD Anderson Cancer Center have now conducted work to assess the role of TXNRD1 in regulating tissue aging.
Katy Rezvani received this year’s E. Donnall Thomas Prize for her work on natural killer (NK) cells at the annual meeting of the American Society of Hematology (ASH). It was not love at first sight, though.
During the IDWeek conference held in Boston earlier this month, presentations on Climate Change were spread throughout the program. Some talks were on the direct effects of weather on infectious agents. Others discussed what healthcare workers could do to mitigate the effects of climate change, from antibiotic stewardship to decarbonization of day to day operations.
At the IDWeek 2023 infectious disease conference held last week in Boston, fungal infections got the audience’s attention during the session titled, “The antifungal evolution: novel strategies for a changing world.” With the emergence of some resistant pathogens such Candida auris and the growing disease burden in the population at risk for life-threatening fungal infections, these pathogens are more than ever standing out within the infectious diseases arena.
Researchers from MD Anderson Cancer Center recently presented the discovery and preclinical evaluation of LLO-CD47, a novel protein-antibody conjugate linking anti-CD47 to Listeriolysin O (LLO), a pore-forming protein secreted by Listeria monocytogenes to escape lysosomes.
Researchers from the MD Anderson Cancer Center presented data from a study that assessed the tumor microenvironment (TME) of adenoid cystic carcinoma (ACC) with the aim of identifying novel therapeutic targets for ACC.
When looking for a name, the founders of startup Nexo Therapeutics Inc., which recently emerged from stealth mode with a $60 million series A financing and a research collaboration with the University of Texas MD Anderson Cancer Center, sought a moniker that truly captured its approach to drug development.
